Clinical trials: Dry Eye Symptoms
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Disease
Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects
The objective of this exploratory study is to determine the safety and efficacy of 0.002% Naltrexone Ophthalmic Solution, compared to placebo for the treatment of the signs and symptoms of dry eye in diabetic subjects.
- Trial name
- NCT03660475
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sassani, Joseph S., MD, MHA
Long Term Follow up Dry Eye Disease
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).
- Trial name
- NCT03920215
- Testing
- OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Oyster Point Pharma, Inc.
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease (DED)
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
- Trial name
- NCT03333057
- Testing
- NOV03
- Where
- 11 sites in United States
- Volunteers
- 336 people
- Sponsor
- Novaliq GmbH
Age-related Macular Degeneration
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received…
- Trial name
- FALCON (NCT04679935)
- Testing
- Brolucizumab
- Where
- 19 sites in Germany, Switzerland
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Keratoconus, Ocular Surface Disease
Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
EYEdeal Scanning Technology enables rapid measurement of corneal and scleral topography. By accurately measuring the ocular surface with this imaging technology, the current iterative fitting method required to fit PROSE…
- Conditions
- Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia
- Trial name
- NCT04649177
- Testing
- Ocular surface optical coherence tomography
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Boston Sight
Dry Eye Syndromes
Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms
This study evaluates the performance and acceptance of Optive versus Hylocomod eyedrops, when administered for one month to patients with mild to moderate dry eye symptoms, with and without contact lenses.
- Trial name
- NCT00761202
- Testing
- A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®, Sodium hyaluronate
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Allergan
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndromes
Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease
In this study, the TearCare System will be compared with standard-of-care warm compress treatment and lid massage in patients with dry eye disease.
- Trial name
- NCT03502447
- Testing
- TearCare, Warm Compress and Lid Massage
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sight Sciences, Inc.
Myopia
A Prospective Study of Two Daily Disposable Contact Lenses
The purpose of this study was to evaluate the performance of a novel silicone hydrogel contact lens, DAILIES TOTAL1® (DT1) compared to the standard hydrogel material in 1-DAY ACUVUE® MOIST® (1DAVM) contact lens in contact lens…
- Trial name
- NCT01636986
- Testing
- Delefilcon A contact lenses, Etafilcon A contact lenses
- Volunteers
- 62 people
- Sponsor
- Alcon Research
Dry Eye Syndrome
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
- Trial name
- NCT01212471
- Testing
- Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- Bausch & Lomb Incorporated
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye…
- Trial name
- SAFARI (NCT02161575)
- Testing
- Ranibizumab
- Where
- 28 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Fibromyalgia, Multiple Sclerosis
e-Mobile Tablet for People With Chronic Conditions
Maintaining a healthy diet and engaging in routine physical activity may help decrease severity of symptoms, prevent secondary conditions, and slow functional decline in people with disabling neuromusculoskeletal conditions.
- Conditions
- Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome
- Trial name
- NCT02833311
- Testing
- Computer Tablet Group, Paper and Pencil Group, Contact Control Group
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Case Western Reserve University
Dry Eye Syndromes
Effect of Intraoperative Dexamethasone on Post-op Dry Eye
To compare the signs and symptoms of dry eye after cataract surgery between subjects randomized to receive intraoperative dexamethasone in addition to the use of a standard topical post-op treatment regimen.
- Trial name
- NCT04184999
- Testing
- dexamethasone intraocular suspension, 9%, Prednisolone Acetate 1% Oph Susp
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- SR Cornea Consultants
Eye Pain
Pilot Study of TENS for Ocular Pain
Approximately 20% of Veterans have a diagnosis of dry eye (DE) syndrome which is often accompanied by ocular pain that significantly impacts activities of daily living.
- Trial name
- NCT05531643
- Testing
- High frequency forehead TENS, Low frequency forehead TENS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Office of Research and Development
Dry Eye, Dry Eye Syndromes
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
This study characterizes acute dry eye symptom control, assessed during exposure to a Controlled Adverse Environment, following use of the TrueTear for 45 days.
- Trial name
- NCT03097614
- Testing
- TrueTear
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Oculeve, Inc.
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
The objective of this pivotal trial is to assess the efficacy, safety and tolerability of CyclASol in comparison to the vehicle for the treatment of signs and symptoms of Dry Eye Disease (DED).
- Trial name
- NCT04523129
- Testing
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Where
- 27 sites in United States
- Volunteers
- 834 people
- Sponsor
- Novaliq GmbH